Ashima Nayyar, Ph.D. is a bioanalytical scientist and Lab Manager in the Department of Neurology at Robert Wood Johnson Medical School, Rutgers University. She specializes in biomarker assay development, validation, and translational research in neurology, oncology, and women’s health, with a particular focus on Alzheimer’s disease and neuroinflammation.
Dr. Nayyar has extensive experience in method development, including LC-MS/MS, ELISA, qPCR, and multiplex platforms, within GLP/GCP-regulated environments. Her work has contributed directly to FDA-cleared assays for Alzheimer’s diagnostics, including the development of the Lumipulse® G pTau 217/Amyloid 1-42 Plasma Ratio Test. She leads high-throughput proteomics and multi-omics analyses, translating biomarker discovery into clinical applications.
Prior to Rutgers, Dr. Nayyar held research positions at the Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, and the Feinstein Institute for Medical Research, where she focused on immune monitoring, exosome biology, and genomics-based biomarker discovery.
Her technical expertise spans cell culture, transgenic mouse models, microscopy, flow cytometry, molecular biology, sequencing, nanotechnology, and immunology. She has led complex biomarker projects, managed cross-functional research teams, and integrated clinical and laboratory data to advance diagnostics and therapeutic strategies.
Dr. Nayyar earned her Ph.D. in Industrial Biotechnology from Abertay University, an M.Sc. in Microbial Technology from Amity University (Gold Medalist), and a B.Sc. (Hons.) in Microbiology from Delhi University. She has authored numerous publications on neurodegeneration, biomarker discovery, exosome biology, and industrial microbiology.